Is gemtuzumab/gemtuzumab (MYLOTARG) covered by medical insurance for reimbursement?

Gemtuzumab/Gemtuzumab (MYLOTARG) is a monoclonal antibody drug used to treat acute myeloid leukemia (AML), especially CD33 positive AML patients. Tocilizumab is a monoclonal antibody, also known as a monoclonal antibody drug. It is a protein manufactured through bioengineering technology that is highly specific and can recognize and bind to specific proteins on the surface of leukemia cells.

Gemtuzumab/GemtuzumabIt is not currently on the market in China, so it cannot be included in medical insurance. Patients cannot purchase it domestically and need to purchase it through overseas channelsGemtuzumab/Gemtuzumab. Foreign Gemtuzumab/Gemtuzumab is only Pfizer’s original drug, which is expensive, and the cheaper ones are mainly Turkish original drugs. The price of the drug is around 45,000 yuan, and the price of the original drug in Hong Kong, China is around 65,000 yuan, and the ingredients and efficacy of the original drug are consistent.

Gemtuzumab/The main mechanism of action of gemtuzumab is to target the CD33 antigen on the surface of AML cells. CD33 is a protein that is highly expressed on AML cells, while normal bone marrow cells usually express less or no CD33. Gemtuzumab/Gemtuzumab can activate the host immune system after binding to CD33 antigen, such as Natural killer cells (NK cells) and macrophages to help destroy CD33-positive AML cells.

Gemtuzumab/Gemtuzumab is commonly used to treat AML patients, especially those who are treatment-naiveAMLCD33positiveAML, and relapsedAMLpatients or AMLpatients who cannot tolerate traditional treatment. It is considered an important drug in the treatment of refractory AML. Gemtuzumab/Gemtuzumab is usually administered by intravenous injection. The specific dosage and treatment plan will be determined based on the patient's specific condition and the doctor's recommendations. Treatment is usually divided into cycles, with each cycle consisting of a certain number of treatments.